No coin nor oath required. For personal study only.
A a-Granules, in platelet, basic biology and clinical correlation of, 177-89 content, 181 formation, 177-80 defects in, 179-80 protein sorting, 178-9 transport, 179 vesicle trafficking, 177-8 functional roles, 181-5 angiogenesis, 183-4 antimicrobial host defense, 183 atherosclerosis, 182-3 coagulation, 181-2 inflammation, 182 malignancy, 184-5 perspective, 185 wound healing, 184 molecular mechanisms, 180-1 Activation-induced cytidine deaminase, as prognostic marker in CLL, 37 Aging, risk for venous thrombosis, 227 Alemtuzumab, for treatment of advanced CLL, 220 Alkaline therapy, as adjunct to haemostatic resuscitation for traumatic haemorrhagic shock, 237 Allogeneic haematopoietic cell transplantation, for treatment of advanced CLL, 219 Alvocidib, for treatment of advanced CLL, 221-2 Angiogenesis marker of, in CLL, 28 role of a-granules in, 183-4 Anticoagulant therapy and cancer survival, 129-30 in management of DIC in obstetric disorders, 172-3 restarting of, in patients with warfarin associated ICH, 6-7 Antigen delivery, in clinical development of lymphoma vaccines, 140-1 Antigen presentation, in clinical development of lymphoma vaccines, 141 Antimicrobial host defense, role of a-granules in, 183 Antiplatelet agents, for atherothrombosis, 73 Antiplatelet therapy, PAR as targets for, 61-65 blocking of, 63-4 clinical development of antagonists for, 64 platelet PARs for thrombus formation, 63 three stage model of platelet activation for, 62 thrombin and thrombin receptors for platelet activation, 63 unmet clinical need
for, 61-2 aspirin, 61 clopidogrel, 61-2 GPIIb-IIIa inhibitors, 62 Antithrombotic therapy and cancer survival, 129-35 anticoagulant therapy, 129-30 coagulation activation, VTE, and tumour cell biology, 130 heparin, 132-3 LMWH, 132-3 UFH, 132 warfarin, 130-2 in high-risk pregnant women with thrombophilia, 144 Aspirin as antiplatelet therapy, 61 for atrial fibrillation, 242-3 Atherosclerosis, role of a-granules in, 182-3 Atherothrombosis, and cardiovascular disease, 69 Atrial fibrillation, oral anticoagulation for treatment of, 241-4 benefits and risks of warfarin, 242 dabigatran etixalate, 243 desired therapeutic range in NRAF, 243 new anticoagulants, 243 orthopaedic thromboprophylaxis, 243-4 prevalence, 241-2 rivaroxaban, 244 stroke, 242 warfarin or aspirin for NRAF, 242-3 B b-blockers, treatment for atherothrombosis, 74 Bcl-2 inhibitors, for treatment of advanced CLL, 222 Biologic response modifiers (BRMs), role in TRALI, 251 Biopsy, for diagnosis of splenomegaly, 108-9 Bleeding, in HDCT, 191-7 bruising, 192-5 Ehlers-Danlos syndrome, 192-4 diagnosis, 195 management in EDS, 195-6 general measures, 195 potential hazards, 195 vasopressin analogue DDAVP and recombinant factor VIIa, 196 mechanisms, 191-2 components of extracellular matrix, 191-2 haemostasis, 192 Blood cells, role in venous thrombosis, 226 Blood coagulability, role in venous thrombosis, 226 Blood products in management of DIC in obstetric disorders, 172 in TRALI avoidance, 251 in transfusion and resuscitation for traumatic haemorrhagic shock, 235-7 support in trauma, 149-55
๐ SIMILAR VOLUMES